Skip to main content

Table 2 Treatment adverse events (n = 14 pts)

From: Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

adevers events

(AEs), n = 14

severity (CTC v. 3) grade

  
 

I

II

III

IV

V

acneiforme skin rash

5 (35.7%)

9 (64.3%)

1 (7.1%)

  

conjunctivitis

 

1 (7.1%)

   

skin fissures

1 (7.1%)

1 (7.1%)

   

mucositis

2 (14.3%)

8 (57.1%)

4 (28.6%)

  

dysphagia

5 (35.7%)

7 (50%)

1 (7.1%)

  

weight loss

1 (7.1%)

1 (7.1%)

   

dermatitis

2 (14.3%)

6 (42.9%)

2 (14.3%)

  

xerostomia

8 (57.1%)

5 (35.7%)

   

laryngeal oedema

3 (21.4%)

    

anemia

 

1 (7.1%)

   

leukopenia

  

1 (7.1%)

  

thrombopenia

   

1 (7.1%)

 

fever

1 (7.1%)

1 (7.1%)

   

hyperkalaemia

1 (7.1%)

    

hypokalaemia

  

2 (14.3%)

  

hypomagnesiaemia

3 (21.4%)

    

nausea

5 (35.7%)

    

oedema

7 (50%)

    

diarrhoea

3 (21.4%)

    

constipation

5 (35.7%)

    

Serious adverse events (SAEs)

    

skin abscess

  

1 (7.1%)

  

arterial embolism

  

1 (7.1%)

  

septic shock

  

1 (7.1%)

  

anaphylactic reaction

 

1 (7.1%)

  

hospital admission due to tonsillitis

1 (7.1%)

  

death due to progressive metastatic disease

  

1 (7.1%)